Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Equity Income (2020 - 2023)

BeOne Medicines (BEIGF) has disclosed Equity Income for 4 consecutive years, with -$3.9 million as the latest value for Q4 2023.

  • Quarterly Equity Income rose 29.29% to -$3.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$8.9 million through Dec 2023, up 71.71% year-over-year, with the annual reading at -$16.2 million for FY2023, 26.25% up from the prior year.
  • Equity Income for Q4 2023 was -$3.9 million at BeOne Medicines, down from -$2.3 million in the prior quarter.
  • The five-year high for Equity Income was $23.8 million in Q3 2021, with the low at -$17.0 million in Q1 2022.
  • Average Equity Income over 4 years is -$1.3 million, with a median of -$2.4 million recorded in 2023.
  • Peak annual rise in Equity Income hit 16718.18% in 2021, while the deepest fall reached 1556.52% in 2021.
  • Over 4 years, Equity Income stood at $1.9 million in 2020, then crashed by 614.79% to -$9.5 million in 2021, then surged by 41.44% to -$5.6 million in 2022, then rose by 29.29% to -$3.9 million in 2023.
  • According to Business Quant data, Equity Income over the past three periods came in at -$3.9 million, -$2.3 million, and -$2.5 million for Q4 2023, Q3 2023, and Q2 2023 respectively.